Coya Therapeutics’ (COYA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report issued on Wednesday,Benzinga reports. D. Boral Capital currently has a $15.00 price objective on the stock.

A number of other analysts also recently weighed in on COYA. Lake Street Capital reiterated a “buy” rating and set a $17.00 target price on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, January 8th. BTIG Research increased their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a report on Monday, November 24th. Finally, Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Coya Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Stock Down 0.2%

Shares of NASDAQ:COYA opened at $4.72 on Wednesday. The company’s 50 day moving average price is $5.54 and its two-hundred day moving average price is $5.94. Coya Therapeutics has a 12-month low of $3.94 and a 12-month high of $8.29. The firm has a market cap of $98.74 million, a PE ratio of -4.25 and a beta of 0.25.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. On average, research analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Dauntless Investment Group LLC grew its holdings in Coya Therapeutics by 199.5% during the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after acquiring an additional 101,932 shares during the last quarter. CM Management LLC grew its position in shares of Coya Therapeutics by 50.0% during the 3rd quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $1,710,000 after buying an additional 100,000 shares during the period. Citadel Advisors LLC grew its position in shares of Coya Therapeutics by 51.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after buying an additional 22,120 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Coya Therapeutics in the 2nd quarter valued at $119,000. Finally, Jane Street Group LLC lifted its position in shares of Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after acquiring an additional 13,176 shares during the period. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.